POS1048 SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL

P. J. Mease, Sibabrata Banerjee, D. van der Heijde et al.|Annals of the Rheumatic Diseases|2022

Cited by 5